Inhibikase Therapeutics, Inc, often referred to as IKT, is a clinical-stage pharmaceutical company specializing in the development of innovative therapeutics for the treatment of several neurological diseases. The primary aim of the company is to provide state-of-the-art, life-altering treatments that can inhibit brain disease.
Founded in 2008 and currently based in Atlanta, Georgia, U.S., the organization has been carrying ground-breaking research in the field of neurological diseases. The Company pioneers in developing reversible protein kinase inhibitors that can replicate the natural genetic response of viral infection.
Inhibikase Therapeutics, Inc. is publicly traded and listed on Nasdaq under the ticker symbol "IKT.". The company's focus lies on Parkinson’s Disease and other related disorders, with an emphasis on addressing the symptoms and complications that arise as these diseases progress.
What makes IKT unique is its approach towards disease treatments. Their therapies are designed to shut off abnormal signal transmission in neurological diseases. Their flagship compound, IkT-148009, targets the Abelson Tyrosine Kinase enzymes in the brain, which are the cause of intracellular dysfunction leading to Parkinson's disease and related disorders.
IKT's offerings are predominantly aimed at treating diseases like Parkinson's and those that are related to ageing. Their most advanced product candidate, IkT-148009, is entering the advanced stages of clinical testing for the treatment of GI and systemic symptoms of Parkinson's disease.
The company's reach and impact are not confined to Parkinson's disease. With its innovative treatment options, it targets a wide range of serious acute and chronic diseases, including progressive multifocal leukoencephalopathy (PML), a rare and deadly viral disease of the brain, and many complications of organ transplant.
Inhibikase Therapeutics, Inc is a prime example of the cutting-edge medical technology that currently exists and the lengths that science has advanced in tackling significant diseases. It prides itself on its focus on diseases that are typically challenging to treat and its dedication to improve the quality of life for those suffering from these conditions. IKT is committed to continuing its research, finding new treatments and therapies for neurological diseases and delivering solutions that will make a significant impact on patients' lives worldwide.